You have read all your free articles, to continue reading subscribe to read the rest of this content.
Nordic Nanovector and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias. Leukemias are orphan diseases with aAlready a subscriber Login You have read all your free…
Shares of Ardelyx dropped in after-market trading earlier this week after the AstraZeneca partner acknowledged that its lead drug tenapanor was unimpressive in a Phase IIa study. Ardelyx, based in California, says that tenapanor missed the primary endpoint among 154 patients with Stage 3 chronic Already a subscriber Login You…
The two companies have entered into a joint research agreement. Under the agreement, Alligator will employ its antibody generation technologies in collaboration with BioArctic to develop new product candidates, it states in a press release. “We are very pleased that BioArctic has recognized Already a subscriber Login You have read…
On May 28th international scientists and experts within outcomes research and patient centred healthcare gathered at the Karolinska Institute to discuss patient-driven development of pharmaceuticals, Swedish quality registers and their role in research, as well as how the patient best could be involAlready a subscriber Login You have read all…
